How Does an Over the Counter Topical called MEBO Scar™ Cosmetically Improve Skin Scars?

Not Applicable

Completed

• Conditions: Cosmetic skin scarring; Skin and Connective Tissue Diseases

• Registration Number: ISRCTN16551998
• Lead Sponsor: niversity of Manchester

Brief Summary

2019 Results article in https://doi.org/10.1089/wound.2018.0864 (added 14/07/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-05-31
• Study Start: 2018-06-07
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Male or female over 18 years old
2. Between 40-150kg (BMI 20-35)
3. Able to understand study requirements and provide written consent

Exclusion Criteria

1. Participants who do not give consent to take part in the study
2. Any subject who in the opinion of the investigator is unable to fully understand the requirements of the trial (for example due to a language barrier), consent or is unable to return for follow-up visits and complete the trial
3. Known allergy to any components of the topical formulation
4. Individuals less than 18 years of age will be excluded from the study
5. Individuals who have a history or evidence of keloid scarring or fibrotic disorders (self reported or determined by physical examination)
6. Participants who are pregnant or are planning to conceive in the next 3 months
7. Participants with a chronic or active skin disorder considered to adversely affect the scar healing by the investigator
8. Participants with any likely healing impairment due to a significant medical condition such as renal, hepatic, haematological, neurological or immune disease, including:
9. Rheumatoid arthritis
10. Chronic renal impairment
11. Diabetes Mellitus
12. Significant hepatic impairment
13. Inadequately or uncontrolled congestive heart failure
14. Malignancy – diagnosed or treated within the past 5 years
15. Immunosuppressive, radiation or chemotherapy within the last three month
16. Participants who are receiving anticoagulant therapy, systemic steroids, hormone replacement therapy or any investigational drugs, or have taken any in the previous month prior to Day 0
17. Participants who have evidence of drug abuse
18. Participants who have had or are known to have serum hepatitis or are carriers of hepatitis B surface antigen, hepatitis B core antibodies or hepatitis C antibodies (previous vaccination against hepatitis B and C is not excluded)
19. Participants who have previously had a positive result to the HIV antibody test, or admit to belong to a high risk group
20. Participants who have been involved in other studies in the past two months prior to Day 0 must discuss the exact details of the previous studies prior to a decision being made of eligibility for inclusion in this trial
21. Exclude participants who are allergic to other amide local anaesthetics
22. Previous MRSA colonisation or infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified